TNYAbenzinga

Tenaya Therapeutics Announced Presentation Of TN-201 Gene Therapy Data For MYBPC3-Associated Hypertrophic Cardiomyopathy At ACC 2025 In Chicago; Includes 1-Year Patient Assessments From MyPEAK-1 Phase 1b/2 Trial

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on March 19, 2025 by benzinga

    Tenaya Therapeutics Announced Presentation Of TN-201 Gene Therapy Data For MYBPC3-Associated Hypertrophic Cardiomyopathy At ACC 2025 In Chicago; Includes 1-Year Patient Assessments From MyPEAK-1 Phase 1b/2 Trial | TNYA Stock News | Candlesense